OncoMatch/Clinical Trials/NCT05694312
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Is NCT05694312 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ibrutinib 420 mg for autoimmune hemolytic anemia.
Treatment: Ibrutinib 420 mg — This is a multicenter, single arm, phase II study aimed at evaluating ibrutinib therapy for the treatment of AIHA in patients with CLL/SLL or CLL-like MBL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Must have received: corticosteroid — AIHA
relapsed after previous treatment with corticosteroids (with or without rituximab), or ... steroid-resistant ... or ... steroid-dependent
Cannot have received: BTK inhibitor (ibrutinib)
Previous exposure to ibrutinib as CLL-directed therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify